Research programme: PPAR modulators - GlaxoSmithKline

Drug Profile

Research programme: PPAR modulators - GlaxoSmithKline

Alternative Names: GSK3787; GW 0742; PPAR agonists research programme - GlaxoSmithKline; PPARpan; Research programme: PPARpan agonists - GlaxoSmithKline

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator GlaxoSmithKline
  • Class Piperazines
  • Mechanism of Action Peroxisome proliferator-activated receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Alzheimer's disease; Cancer; Diabetes mellitus; Lipid metabolism disorders; Metabolic syndrome

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Alzheimer's-disease in USA (PO)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer in USA
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Diabetes-mellitus in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top